{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:18:40Z","timestamp":1783369120855,"version":"3.54.6"},"reference-count":80,"publisher":"Elsevier","isbn-type":[{"value":"9780443470387","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apha.2026.05.008","type":"book-chapter","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:25:53Z","timestamp":1780957553000},"page":"101-116","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing the persistence of therapeutic T cells"],"prefix":"10.1016","author":[{"given":"Gregory M.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.apha.2026.05.008_bib1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2026.05.008_bib2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","article-title":"Circulating tumor cells: Liquid biopsy of cancer","volume":"59","author":"Alix-Panabi\u00e8res","year":"2013","journal-title":"Clinical Chemistry"},{"key":"10.1016\/bs.apha.2026.05.008_bib4","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/hum.2013.075","article-title":"Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia","volume":"24","author":"Barrett","year":"2013","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.apha.2026.05.008_bib7","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1089\/hum.2011.070","article-title":"Treatment of advanced leukemia in mice with mRNA engineered T cells","volume":"22","author":"Barrett","year":"2011","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.apha.2026.05.008_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.apha.2026.05.008_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.apha.2026.05.008_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.apha.2026.05.008_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278950","article-title":"Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center","volume":"17","author":"Chacim","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/bs.apha.2026.05.008_bib12","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","author":"Chen","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apha.2026.05.008_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3353","article-title":"B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?","volume":"14","author":"Chen","year":"2022","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib14","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2026.05.008_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","article-title":"\u03b3\u03b4 T cells: FIrst line of defense and beyond","volume":"32","author":"Chien","year":"2014","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.008_bib17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apha.2026.05.008_bib18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.apha.2026.05.008_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical applications of gamma delta T cells with multivalent immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib20","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1002\/cam4.2474","article-title":"Are 90% of deaths from cancer caused by metastases?","volume":"8","author":"Dillek\u00e5s","year":"2019","journal-title":"Cancer Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp9371","article-title":"TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function","volume":"10","author":"Dimitri","year":"2024","journal-title":"Science Advances"},{"key":"10.1016\/bs.apha.2026.05.008_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/25374","article-title":"Changes in thymic function with age and during the treatment of HIV infection","volume":"396","author":"Douek","year":"1998","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08830185.2013.783831","article-title":"Gammadelta T cells: Innately adaptive immune cells?","volume":"32","author":"Ferreira","year":"2013","journal-title":"International Reviews of Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib25","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2026.05.008_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0167-5699(96)80543-3","article-title":"Thymic involution with ageing: Obsolescence or good housekeeping?","volume":"17","author":"George","year":"1996","journal-title":"Immunology Today"},{"key":"10.1016\/bs.apha.2026.05.008_bib28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","article-title":"Mechanisms governing metastatic dormancy and reactivation","volume":"155","author":"Giancotti","year":"2013","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2026.05.008_bib29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: Building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2026.05.008_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-018-0164-6","article-title":"The journey to CAR T cell therapy: The pediatric and young adult experience with relapsed or refractory B-all","volume":"9","author":"Hucks","year":"2019","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/bs.apha.2026.05.008_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3-induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nbt955","article-title":"The ABCs of artificial antigen presentation","volume":"22","author":"Kim","year":"2004","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.apha.2026.05.008_bib34","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib35","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.ade0156","article-title":"Multidimensional control of therapeutic human cell function with synthetic gene circuits","volume":"378","author":"Li","year":"2022","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apha.2026.05.008_bib36","article-title":"Abstract LB-380: Novel coupledCARTMtechnology for treating colorectal cancer","author":"Li","year":"2020","journal-title":"Bioinformatics, Convergence Science, and Systems Biology (American Association for Cancer Research)"},{"key":"10.1016\/bs.apha.2026.05.008_bib37","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"key":"10.1016\/bs.apha.2026.05.008_bib38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cpt.2040","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans","volume":"109","author":"Liu","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/bs.apha.2026.05.008_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apha.2026.05.008_bib42","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib43","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2026.05.008_bib46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib47","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.4049\/jimmunol.174.11.7446","article-title":"The influence of age on T cell generation and TCR diversity","volume":"174","author":"Naylor","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fimmu.2013.00316","article-title":"The effect of age on thymic function","volume":"4","author":"Palmer","year":"2013","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-023-00837-3","article-title":"Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL","volume":"13","author":"Qiu","year":"2023","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/bs.apha.2026.05.008_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-182728","article-title":"Safety and efficacy of CD22\/ CD19 CAR-T and auto-HSCT \u201cSandwich\u201d strategy as consolidation therapy for Ph negative B cell acute lymphoblastic leukemia","volume":"142","author":"Qiu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.008_bib52","article-title":"Abstract 2569: CAR19 T cells secreting antigen-retargeting fusion proteins have remarkable potency against diverse tumor types","author":"Rennert","year":"2018","journal-title":"Immunology (American Association for Cancer Research)"},{"key":"10.1016\/bs.apha.2026.05.008_bib53","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.18632\/oncotarget.12739","article-title":"The concept of immune surveillance against tumors. The first theories","volume":"8","author":"Ribatti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.apha.2026.05.008_bib54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.apha.2026.05.008_bib55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apha.2026.05.008_bib56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apha.2026.05.008_bib57","doi-asserted-by":"crossref","first-page":"eaeb2970","DOI":"10.1126\/sciadv.aeb2970","article-title":"Age-related thymic involution: Mechanistic insights and rejuvenating approaches to restore immune function","volume":"12","author":"Santamaria","year":"2026","journal-title":"Science Advances"},{"key":"10.1016\/bs.apha.2026.05.008_bib58","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/bs.apha.2026.05.008_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/imr.12137","article-title":"A new approach to gene therapy using sleeping beauty to genetically modify clinical-grade T cells to target CD19","volume":"257","author":"Singh","year":"2014","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.apha.2026.05.008_bib60","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.apha.2026.05.008_bib62","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"key":"10.1016\/bs.apha.2026.05.008_bib63","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jcyt.2020.08.005","article-title":"Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells","volume":"22","author":"\u0160tach","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/bs.apha.2026.05.008_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-083122-040929","article-title":"The CD4 versus CD8 T cell fate decision: A multiomics-informed perspective","volume":"42","author":"Steier","year":"2024","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-82480-7_2","article-title":"Changes in the human thymus during aging","volume":"75","author":"Steinmann","year":"1986","journal-title":"Current Topics in Pathology. Ergebnisse der Pathologie"},{"key":"10.1016\/bs.apha.2026.05.008_bib66","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2026.05.008_bib67","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.apha.2026.05.008_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-6297","article-title":"Persistent B-cell aplasia predicts late severe infections after anti-CD19 CAR T-cell treatment in B-cell lymphoma: A methodological approach to long-term safety reporting","volume":"146","author":"Tilmont","year":"2025","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.008_bib69","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2026.05.008_bib70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-018-0001-y","article-title":"The full spectrum of human naive T cells","volume":"18","author":"van den Broek","year":"2018","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib71","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: Foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Molecular Therapy Oncology"},{"key":"10.1016\/bs.apha.2026.05.008_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clinical & Translational Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111311","article-title":"Distinct gene expression by expanded clones of quiescent memory CD4+ T cells harboring intact latent HIV-1 proviruses","volume":"40","author":"Weymar","year":"2022","journal-title":"Cell Reports"},{"key":"10.1016\/bs.apha.2026.05.008_bib75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib76","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nature Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib77","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.008_bib78","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-15-1370","article-title":"Mechanisms of cancer cell dormancy--another hallmark of cancer?","volume":"75","author":"Yeh","year":"2015","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apha.2026.05.008_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611710","article-title":"How to combine the two landmark treatment methods-allogeneic hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy together to cure high-risk B cell acute lymphoblastic leukemia?","volume":"11","author":"Zhang","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apha.2026.05.008_bib80","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/s12967-021-03165-x","article-title":"Optimization of metabolism to improve efficacy during CAR-T cell manufacturing","volume":"19","author":"Zhang","year":"2021","journal-title":"Journal of Translational Medicine"}],"container-title":["Advances in Pharmacology","Pharmacology of T-Cell Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:46:48Z","timestamp":1783367208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358926000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443470387"],"references-count":80,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2026.05.008","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}